Oragenics, Inc. — Q2 2012 Form 10-Q
Business context and reporting period
For the quarter and six months ended June 30, 2012. Oragenics develops oral-health products and biopharmaceutical candidates. Its commercial product line is ProBiora3 oral probiotics; development programs include SMaRT Replacement Therapy and the MU1140-S antibiotic. In June 2012, it entered an exclusive collaboration with Intrexon to develop lantibiotics.
Financial performance and liquidity
| Metric | Three months 2012 | Three months 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Net revenue | $256,407 | $347,569 | $636,934 | $697,506 |
| Gross profit | $144,149 | $18,752 | $326,467 | $273,712 |
| Gross margin | 56.2% | 5.4% | 51.3% | 39.2% |
| Operating expenses | $7,012,848 | $2,323,126 | $8,674,040 | $4,093,473 |
| Net loss | $6,928,771 | $2,373,243 | $8,545,679 | $3,932,256 |
| Basic and diluted loss per share | $0.52 | $0.42 | $0.86 | $0.69 |
- Six-month operating cash use was $2,292,991, compared with $2,584,733 in 2011. Cash and cash equivalents were $1,130,486 at June 30, up from $171,739 at year-end; restricted cash was a further $195,388.
- Current assets were $1,871,444 and current liabilities $1,375,504, giving reported working capital of $495,940. The balance sheet also showed a $2,056,030 shareholder note payable and a total shareholders’ deficit of $1,448,599.
- June-quarter R&D included a $5,798,001 noncash Intrexon technology-access fee, paid in 4,392,425 shares. This was the principal reason for the sharply higher R&D expense and net loss.
- The balance sheet reflects conversion of $8,737,011 of prior KFLP debt and accrued interest into common stock and warrants in March. Six-month financing cash inflows included $2.5 million of new KFLP borrowing. The $2.5 million secured KFLP loan outstanding at June 30 was converted into 1,692,123 shares after quarter-end.
Changes versus the prior comparable period
Six-month revenue declined 8.7% year over year. Management attributed the ProBiora3 sales decline to reduced advertising and promotional spending. Cost of sales fell, primarily because of lower scrap expense, lifting gross margin. R&D increased by $5.49 million, mainly because of the Intrexon share-based access fee; excluding the fee, reported R&D was lower than in the prior-year period. SG&A declined 29.7%, reflecting lower marketing, compensation, and stock-based compensation costs, partly offset by higher legal, professional, and temporary labor costs. Interest expense increased by $86,914 for the six-month period.
Outlook, risks, and unusual items
- On July 30, 2012, the company sold 8,666,665 shares at $1.50 each for approximately $13 million gross proceeds. The placement agent received a $899,698 cash commission, may receive reimbursement of expenses up to $50,000, and received warrants for 771,169 shares at $1.50. Management said the proceeds would support lantibiotics development, probiotic sales and marketing, and general corporate purposes.
- Management stated that July 31 working capital, together with available resources, was expected to fund the current business plan through at least December 2013; elsewhere it described funding for at least 18 months. Management also cautioned that further capital may be needed and may not be available on acceptable terms. The prior-year audit report had raised substantial doubt about the company’s ability to continue as a going concern; management believed the financing addressed that concern, but did not eliminate future funding risk.
- Management expects significant losses and cash needs to continue. It planned to advance SMaRT and MU1140-S development, subject to capital availability; the filing cites expected MU1140-S preclinical work and an IND filing target in mid-2014. SMaRT’s second Phase 1 trial was expected to conclude in the second half of 2012. The non-attenuated SMaRT IND remained under FDA clinical hold.
- Under the Intrexon agreement, Oragenics is responsible for substantial development funding and will pay Intrexon 25% of specified product gross profits or 50% of specified sublicensing revenue. Additional share or cash payments are due upon development and regulatory milestones; dilution and ongoing program costs are important considerations.
- Key risks include early-stage clinical and regulatory uncertainty, dependence on additional financing and partners, modest ProBiora3 revenue, manufacturing and supplier dependence, and potential dilution. The company reported that disclosure controls were not effective because material weaknesses remained, including limited control documentation, insufficient personnel for segregation of duties, and lack of formal accounting and reporting procedures. No material legal proceedings were reported.
Important facts for investors to verify
- Reconcile the filing’s differing figures: the cash flow statement reports financing cash flow of $3,251,738, while MD&A states $3,215,738; the notes describe six-month revenue as $636,934, while one MD&A passage says $639,934.
- Confirm the net proceeds from the July financing after placement fees and expenses, and track the intended use of proceeds against the company’s stated operating runway.
- Assess the fully diluted share count and potential dilution from the offering, KFLP and placement-agent warrants, Intrexon milestone shares, and incentive-plan awards. The filing reports 27,204,721 common shares outstanding as of August 6, 2012.
- Monitor development timelines, trial results, FDA status of the SMaRT INDs, and the costs and obligations under the Intrexon collaboration and University of Florida licenses.
- Follow remediation of internal-control material weaknesses and any subsequent going-concern assessment.